Lipidomic analysis of serum from high fat diet induced obese mice

International Journal of Molecular Sciences

Volumn 15, Issue 2, 2014, Pages 2991-3002

  Eisinger, Kristina ^a   Liebisch, Gerhard ^a   Schmitz, Gerd ^a   Aslanidis, Charalampos ^a   Krautbauer, Sabrina ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Lipidomic profiling; Lysophosphatidylcholine; Obesity; Phospholipids; Serum

Indexed keywords

CHEMERIN; CHOLESTEROL ESTER; GLUCOSE; INSULIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; SPHINGOMYELIN; TRIACYLGLYCEROL; CHOLESTEROL; LIPID;

ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; OBESITY; SERUM; ANIMAL; BLOOD; C57BL MOUSE; METABOLISM; MOUSE MUTANT;

ANIMALS; BODY WEIGHT; CHOLESTEROL; DIET, HIGH-FAT; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLINOSITOLS; SPHINGOMYELINS; TRIGLYCERIDES;

EID: 84894282174     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15022991     Document Type: Article

References (38)

1. Boden, G.; Shulman, G.I. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Investig. 2002, 32, 14-23.
2. Ogden, C.L.; Carroll, M.D.; Curtin, L.R.; McDowell, M.A.; Tabak, C.J.; Flegal, K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295, 1549-1555.
3. Buechler, C.; Wanninger, J.; Neumeier, M. Adiponectin, a key adipokine in obesity related liver diseases. World J. Gastroenterol. 2011, 17, 2801-2811.
4. Taskinen, M.R. Type 2 diabetes as a lipid disorder. Curr. Mol. Med. 2005, 5, 297-308.
5. Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J.; et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004, 364, 937-952.
6. Quehenberger, O.; Armando, A.M.; Brown, A.H.; Milne, S.B.; Myers, D.S.; Merrill, A.H.; Bandyopadhyay, S.; Jones, K.N.; Kelly, S.; Shaner, R.L.; et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 2010, 51, 3299-3305.
7. Pietilainen, K.H.; Sysi-Aho, M.; Rissanen, A.; Seppanen-Laakso, T.; Yki-Jarvinen, H.; Kaprio, J.; Oresic, M. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study. PLoS One 2007, 2, e218.
8. Kim, J.Y.; Park, J.Y.; Kim, O.Y.; Ham, B.M.; Kim, H.J.; Kwon, D.Y.; Jang, Y.; Lee, J.H. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J. Proteome Res. 2010, 9, 4368-4375.
9. Floegel, A.; Stefan, N.; Yu, Z.; Muhlenbruch, K.; Drogan, D.; Joost, H.G.; Fritsche, A.; Haring, H.U.; Hrabe de Angelis, M.; Peters, A.; et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013, 62, 639-648.
10. Barber, M.N.; Risis, S.; Yang, C.; Meikle, P.J.; Staples, M.; Febbraio, M.A.; Bruce, C.R. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 2012, 7, e41456.
11. Kim, H.J.; Kim, J.H.; Noh, S.; Hur, H.J.; Sung, M.J.; Hwang, J.T.; Park, J.H.; Yang, H.J.; Kim, M.S.; Kwon, D.Y.; et al. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J. Proteome Res. 2011, 10, 722-731.
12. An, Y.; Xu, W.; Li, H.; Lei, H.; Zhang, L.; Hao, F.; Duan, Y.; Yan, X.; Zhao, Y.; Wu, J.; et al. High-fat diet induces dynamic metabolic alterations in multiple biological matrices of rats. J. Proteome Res. 2013, 12, 3755-3768.
13. Boini, K.M.; Zhang, C.; Xia, M.; Poklis, J.L.; Li, P.L. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 2010, 334, 839-846.
14. Shah, C.; Yang, G.; Lee, I.; Bielawski, J.; Hannun, Y.A.; Samad, F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J. Biol. Chem. 2008, 283, 13538-13548.
15. Fox, T.E.; Bewley, M.C.; Unrath, K.A.; Pedersen, M.M.; Anderson, R.E.; Jung, D.Y.; Jefferson, L.S.; Kim, J.K.; Bronson, S.K.; Flanagan, J.M.; et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J. Lipid Res. 2011, 52, 509-517.
16. Boon, J.; Hoy, A.J.; Stark, R.; Brown, R.D.; Meex, R.C.; Henstridge, D.C.; Schenk, S.; Meikle, P.J.; Horowitz, J.F.; Kingwell, B.A.; et al. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 2013, 62, 401-410.
17. Haus, J.M.; Kashyap, S.R.; Kasumov, T.; Zhang, R.; Kelly, K.R.; Defronzo, R.A.; Kirwan, J.P. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009, 58, 337-343.
18. Holland, W.L.; Brozinick, J.T.; Wang, L.P.; Hawkins, E.D.; Sargent, K.M.; Liu, Y.; Narra, K.; Hoehn, K.L.; Knotts, T.A.; Siesky, A.; et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5, 167-179.
19. Liu, S.; Brown, J.D.; Stanya, K.J.; Homan, E.; Leidl, M.; Inouye, K.; Bhargava, P.; Gangl, M.R.; Dai, L.; Hatano, B.; et al. A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature 2013, 502, 550-554.
20. Bauer, S.; Wanninger, J.; Schmidhofer, S.; Weigert, J.; Neumeier, M.; Dorn, C.; Hellerbrand, C.; Zimara, N.; Schaffler, A.; Aslanidis, C.; et al. Sterol regulatory element-binding protein 2 (SREBP2) activation after excess triglyceride storage induces Chemerin in hypertrophic adipocytes. Endocrinology 2011, 152, 26-35.
21. Bozaoglu, K.; Bolton, K.; McMillan, J.; Zimmet, P.; Jowett, J.; Collier, G.; Walder, K.; Segal, D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148, 4687-4694.
22. Lee, R.G.; Kelley, K.L.; Sawyer, J.K.; Farese, R.V., Jr.; Parks, J.S.; Rudel, L.L. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a: Cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ. Res. 2004, 95, 998-1004.
23. Chavez, J.A.; Summers, S.A. A ceramide-centric view of insulin resistance. Cell Metab. 2012, 15, 585-594.
24. Matsumoto, T.; Kobayashi, T.; Kamata, K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr. Med. Chem. 2007, 14, 3209-3220.
25. Roberts, C.K.; Liang, K.; Barnard, R.J.; Kim, C.H.; Vaziri, N.D. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. Kidney Int. 2004, 66, 1503-1511.
26. Samad, F.; Hester, K.D.; Yang, G.; Hannun, Y.A.; Bielawski, J. Altered adipose and plasma sphingolipid metabolism in obesity: A potential mechanism for cardiovascular and metabolic risk. Diabetes 2006, 55, 2579-2587.
27. Ichi, I.; Nakahara, K.; Kiso, K.; Kojo, S. Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. Nutrition 2007, 23, 570-574.
28. Masi, L.N.; Rodrigues, A.C.; Curi, R. Fatty acids regulation of inflammatory and metabolic genes. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16, 418-424.
29. Lankinen, M.; Schwab, U.; Kolehmainen, M.; Paananen, J.; Poutanen, K.; Mykkanen, H.; Seppanen-Laakso, T.; Gylling, H.; Uusitupa, M.; Oresic, M. Whole grain products, fish and bilberries alter glucose and lipid metabolism in a randomized, controlled trial: The Sysdimet study. PLoS One 2011, 6, e22646.
30. Szymanska, E.; van Dorsten, F.A.; Troost, J.; Paliukhovich, I.; van Velzen, E.J.; Hendriks, M.M.; Trautwein, E.A.; van Duynhoven, J.P.; Vreeken, R.J.; Smilde, A.K. A lipidomic analysis approach to evaluate the response to cholesterol-lowering food intake. Metabolomics 2012, 8, 894-906.
31. Floegel, A.; von Ruesten, A.; Drogan, D.; Schulze, M.B.; Prehn, C.; Adamski, J.; Pischon, T.; Boeing, H. Variation of serum metabolites related to habitual diet: A targeted metabolomic approach in EPIC-Potsdam. Eur. J. Clin. Nutr. 2013, 67, 1100-1108.
32. Li, Z.; Agellon, L.B.; Vance, D.E. A role for high density lipoproteins in hepatic phosphatidylcholine homeostasis. Biochim. Biophys. Acta 2007, 1771, 893-900.
33. Ober, C.; Loisel, D.A.; Gilad, Y. Sex-specific genetic architecture of human disease. Nat. Rev. Genet. 2008, 9, 911-922.
34. Liebisch, G.; Lieser, B.; Rathenberg, J.; Drobnik, W.; Schmitz, G. High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm. Biochim. Biophys. Acta 2004, 1686, 108-117.
35. Matyash, V.; Liebisch, G.; Kurzchalia, T.V.; Shevchenko, A.; Schwudke, D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 2008, 49, 1137-1146.
36. Liebisch, G.; Drobnik, W.; Reil, M.; Trumbach, B.; Arnecke, R.; Olgemoller, B.; Roscher, A.; Schmitz, G. Quantitative measurement of different ceramide species from crude cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS/MS). J. Lipid Res. 1999, 40, 1539-1546.
37. Liebisch, G.; Binder, M.; Schifferer, R.; Langmann, T.; Schulz, B.; Schmitz, G. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim. Biophys. Acta 2006, 1761, 121-128.
38. Liebisch, G.; Vizcaino, J.A.; Kofeler, H.; Trotzmuller, M.; Griffiths, W.J.; Schmitz, G.; Spener, F.; Wakelam, M.J. Shorthand notation for lipid structures derived from mass spectrometry. J. Lipid Res. 2013, 54, 1523-1530.